Innovation Pharmaceuticals Inc (IPIX)

[thefamilyman]

In the ABSSSI trial, Brilacidin may have had twice the number of AEs but Brilacidin also had three times the number of patients. There were 4 equally powered arms in that trial; 3 for varying doses of Brilacidin and 1 for the standard Daptomycin dosing protocol. So given these facts, Brilacidin actually had a better AE profile than Daptomycin.

Sunspotter said,

How do you account for the fact that brilacidin had twice as many patients experiencing at least one AE in this study than the active comparator, daptomycin?